Tricida, Inc. (NASDAQ:TCDA – Get Rating) major shareholder Venrock Healthcare Capital Par purchased 268,736 shares of the firm’s stock in a transaction on Monday, October 3rd. The stock was acquired at an average price of $11.27 per share, for a total transaction of $3,028,654.72. Following the completion of the transaction, the insider now directly owns 9,318,800 shares of the company’s stock, valued at approximately $105,022,876. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Wednesday, September 28th, Venrock Healthcare Capital Par purchased 76,600 shares of Tricida stock. The stock was acquired at an average price of $9.92 per share, for a total transaction of $759,872.00.
- On Monday, September 26th, Venrock Healthcare Capital Par purchased 395,614 shares of Tricida stock. The stock was acquired at an average price of $8.56 per share, for a total transaction of $3,386,455.84.
- On Friday, July 29th, Venrock Healthcare Capital Par purchased 18,900 shares of Tricida stock. The stock was acquired at an average price of $9.21 per share, for a total transaction of $174,069.00.
- On Monday, July 25th, Venrock Healthcare Capital Par acquired 29,199 shares of Tricida stock. The stock was purchased at an average cost of $8.95 per share, with a total value of $261,331.05.
- On Friday, July 22nd, Venrock Healthcare Capital Par acquired 15,000 shares of Tricida stock. The stock was purchased at an average cost of $9.21 per share, with a total value of $138,150.00.
- On Wednesday, July 20th, Venrock Healthcare Capital Par acquired 25,000 shares of Tricida stock. The stock was purchased at an average cost of $9.54 per share, with a total value of $238,500.00.
- On Monday, July 18th, Venrock Healthcare Capital Par acquired 100,000 shares of Tricida stock. The stock was purchased at an average cost of $9.02 per share, with a total value of $902,000.00.
- On Thursday, July 14th, Venrock Healthcare Capital Par acquired 36,717 shares of Tricida stock. The stock was purchased at an average cost of $9.85 per share, with a total value of $361,662.45.
- On Tuesday, July 12th, Venrock Healthcare Capital Par acquired 25,000 shares of Tricida stock. The stock was purchased at an average cost of $9.81 per share, with a total value of $245,250.00.
- On Tuesday, July 5th, Venrock Healthcare Capital Par acquired 32,500 shares of Tricida stock. The stock was purchased at an average cost of $9.53 per share, with a total value of $309,725.00.
Tricida Trading Up 5.5 %
TCDA traded up $0.58 during trading on Monday, hitting $11.06. 1,580,576 shares of the company traded hands, compared to its average volume of 501,027. The company has a market cap of $615.70 million, a PE ratio of -4.08 and a beta of 0.61. The stock’s 50-day simple moving average is $11.31 and its two-hundred day simple moving average is $10.09. Tricida, Inc. has a 1 year low of $4.10 and a 1 year high of $13.85.
Tricida (NASDAQ:TCDA – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.03. Equities analysts expect that Tricida, Inc. will post -2.07 EPS for the current year.
Hedge Funds Weigh In On Tricida
Several institutional investors have recently bought and sold shares of TCDA. Frazier Life Sciences Management L.P. purchased a new position in Tricida during the first quarter valued at $17,115,000. Commodore Capital LP purchased a new position in shares of Tricida in the 4th quarter worth $11,922,000. State Street Corp grew its stake in shares of Tricida by 415.5% in the 2nd quarter. State Street Corp now owns 547,419 shares of the company’s stock worth $5,299,000 after buying an additional 441,221 shares in the last quarter. Deep Track Capital LP grew its stake in shares of Tricida by 13.6% in the 1st quarter. Deep Track Capital LP now owns 2,652,693 shares of the company’s stock worth $21,805,000 after buying an additional 317,550 shares in the last quarter. Finally, J. Goldman & Co LP purchased a new position in shares of Tricida in the 1st quarter worth $2,238,000.
About Tricida
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tricida, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tricida wasn’t on the list.
While Tricida currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Purchases $3,028,654.72 in Stock